- Home
- NI vs UTHR Comparison
NI vs UTHR Comparison
Compare NI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NI
- UTHR
- Stock Information
- Founded
- NI 1912
- UTHR 1996
- Country
- NI United States
- UTHR United States
- Employees
- NI N/A
- UTHR N/A
- Industry
- NI Power Generation
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- NI Utilities
- UTHR Health Care
- Exchange
- NI Nasdaq
- UTHR Nasdaq
- Market Cap
- NI 17.6B
- UTHR 16.1B
- IPO Year
- NI N/A
- UTHR 1999
- Fundamental
- Price
- NI $38.01
- UTHR $356.95
- Analyst Decision
- NI Strong Buy
- UTHR Buy
- Analyst Count
- NI 8
- UTHR 14
- Target Price
- NI $37.50
- UTHR $378.36
- AVG Volume (30 Days)
- NI 3.6M
- UTHR 301.3K
- Earning Date
- NI 02-19-2025
- UTHR 02-19-2025
- Dividend Yield
- NI 2.99%
- UTHR N/A
- EPS Growth
- NI 9.78
- UTHR 25.10
- EPS
- NI 1.64
- UTHR 22.72
- Revenue
- NI $5,289,300,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- NI $12.31
- UTHR $26.19
- Revenue Next Year
- NI $4.21
- UTHR $10.79
- P/E Ratio
- NI $22.78
- UTHR $15.55
- Revenue Growth
- NI N/A
- UTHR 25.04
- 52 Week Low
- NI $24.80
- UTHR $208.62
- 52 Week High
- NI $38.83
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- NI 55.87
- UTHR 45.31
- Support Level
- NI $36.55
- UTHR $344.36
- Resistance Level
- NI $37.77
- UTHR $358.63
- Average True Range (ATR)
- NI 0.77
- UTHR 10.38
- MACD
- NI 0.02
- UTHR -1.35
- Stochastic Oscillator
- NI 61.00
- UTHR 34.38
About NI NiSource Inc
NiSource is one of the nation's largest natural gas distribution companies with approximately 3.2 million customers in Indiana, Kentucky, Maryland, Ohio, Pennsylvania, and Virginia. NiSource's electric utility transmits and distributes electricity in northern Indiana to about 500,000 customers. The regulated electric utility also owns more than 3,000 megawatts of generation capacity, including coal, natural gas, and renewable energy.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.